Tirzepatide side effects need separate entries
Some are frequent symptoms, some are trial signals, and some are label precautions. Their differences matter.
Mild or moderate can still end treatment
Nausea, vomiting, diarrhea, constipation and decreased appetite dominate the gastrointestinal record. In SURMOUNT-1, nausea was reported in about 25% at 5 mg and about 30–33% at 15 mg; vomiting in about 8% and 11%, respectively. Diarrhea affected about 16–20% and constipation about 10–15%. These observations describe the trial population; an individual forecast would go further.
The 2023 gastrointestinal review documented the dose-related pattern. In the 2025 pooled obesity-trial analysis, the overall gastrointestinal adverse-event relative risk with tirzepatide was 2.94 versus placebo, with a 95% confidence interval of 2.61 to 3.32. That compares risks between groups; the fraction of all users with symptoms is a different measure.
The dulaglutide comparison review found 32% higher discontinuation due to adverse events with tirzepatide, mostly driven by gastrointestinal effects. I’d give those withdrawals more weight than a comforting severity adjective. Tolerability is consequential even when the event is not classified as serious.
Gallbladder and pancreas are different records
The 2023 analysis of nine randomized trials and 9,871 participants found an increased combined gallbladder-or-biliary-disease outcome: relative risk 1.97, 95% confidence interval 1.14 to 3.42. The individual components did not each reach significance. Pancreatitis was not significantly increased: relative risk 1.46, interval 0.59 to 3.61.
A 2025 analysis of 12 trials found increased gallbladder/biliary disease, relative risk 1.52, and gallstones, relative risk 1.67. The broader incretin-class analysis found about 26% more gallbladder disorders. Rapid weight reduction itself can precipitate gallstones, so a causal account has to accommodate the weight change as well as the medicine.
There is also a qualification within the pooled evidence: the obesity-without-diabetes gastrointestinal analysis did not find a significant biliary signal for tirzepatide. Its population and included trials differ from the dedicated gallbladder reviews. I’m unwilling to iron that difference flat; the dedicated reviews support concern without making every analysis agree.
The retrospective pancreatitis-recurrence cohort observed lower five-year recurrence among tirzepatide users with a prior episode. That association leaves prevention unproven. The label still flags pancreatitis; severe persistent abdominal pain needs prompt medical assessment.
The thyroid warning is animal evidence with human consequences
The boxed FDA warning rests on thyroid C-cell tumors in rodents. Whether tirzepatide causes those tumors in humans is uncertain. The label contraindicates it with a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, usually shortened to MEN-2.
The 2025 cancer-risk review did not establish an overall rise in human cancer in the record summarized here. That does not abolish a warning about a particular tumor or provide lifetime follow-up. My objection runs both ways: treating the rodent result as proven human harm is wrong, and treating uncertainty as clearance is wrong, too.
A neck lump, persistent hoarseness, difficulty swallowing or shortness of breath warrants medical assessment. Those symptoms are not a diagnosis supplied by this page. The clinical-reference chapter provides additional context for the label restrictions.
Other medicines and other settings change the risk
The label precautions about insulin and sulfonylureas concern increased hypoglycemia risk when these are used alongside tirzepatide. On its own, its insulin effect depends on blood glucose. Changes to accompanying medicines are prescribing decisions. The post hoc analysis in older adults without obesity cannot stand in for assessing one person's combination of medicines.
Severe vomiting or diarrhea can cause dehydration and may precipitate acute kidney injury, particularly with diuretics, ACE inhibitors or ARBs. The safety review distinguishes that mechanistic concern from large datasets that do not show a significant overall increase in acute kidney injury.
Delayed gastric emptying can alter absorption of oral medicines, including hormonal contraceptives; the contraceptive label precaution applies especially around initiation and dose increases. Around endoscopy, sedation or anesthesia, retained gastric contents raise another caution. Documented aspiration is rare, and evidence for management is limited. A single universal procedure schedule would claim more than this record supports.
Reports start investigations; they do not supply incidence
The 2025 FAERS analysis found incorrect dose administration was the most frequently reported event, followed by injection-site and gastrointestinal events. The 2026 gastrointestinal reporting analysis found a median onset of 16 days, with most reported events in the first three months. The type 2 diabetes reporting analysis also identified gastrointestinal and injection-site signals. These databases collect reports, not a randomized comparison or a complete count of exposed people.
Hair shedding appears in the case-based hair-loss report, often attributed to rapid weight reduction and reduced nutrient intake. The current trial summaries record approximately 4–5% with tirzepatide versus 1% with placebo; that does not prove the cause of an individual episode.
Lean-mass loss and weight regain after stopping deserve room, too, as distinct events from nausea or a gallstone. The weight-loss account follows both. I’d rather leave several distinct concerns visible than manufacture one safety score from incompatible measurements.